Abcam and Molecular Devices Announce Strategic Collaboration

Abcam today announced a strategic collaboration to develop a wide range of fast and reproducible screening tools for researchers.

First CatchPoint® SimpleStep® ELISA kits launching at SLAS 2018, Feb 3-7, San Diego, USA

Cambridge, UK and San Jose, CA, USA – 5 February 2018 – Abcam, a global innovator in life science reagents and tools, and Molecular Devices, a leading provider of high-performance bioanalytical measurement solutions for the life science industry, today announced a strategic collaboration to develop a wide range of fast and reproducible screening tools for researchers.

The initial collaboration combines proprietary technologies from both organisations to create high sensitivity fluorescent ELISA kits, which are immunoassays used to quantify target proteins in basic research, high throughput screening and diagnostics. The immunoassay market is estimated to reach over $25bn by 2019 due to increased use in cancer, infectious diseases and the introduction of novel biomarkers1.

John Baker, SVP Portfolio and Business Development said: “Collaborating with other leading organisations like Molecular Devices allows us to combine the latest technologies and rapidly provide researchers with innovative tools that will help accelerate their work. We are excited to be launching the first of our combined kits at SLAS2018 and are looking forward to creating further tools that will bring measurable benefit to the industry.”

Scott Greenstone, Director of Open Innovation and Reagents at Molecular Devices, commented: “We are thrilled to offer our customers this new combination of our proven CatchPoint fluorescence technology with Abcam’s high-quality antibodies and ELISA expertise. Optimized for our industry-leading plate readers, these kits will provide customers with a cohesive solution that enables better results faster. We believe this collaborative approach to new product development is a winning combination for customers and we will be working together throughout 2018 to further expand the offering.”

With an industry demand for fast, easy-to-use and sensitive ELISAs, the new CatchPoint SimpleStep ELISA kits combine the simplicity and speed of Abcam’s SimpleStep ELISA protocol, with its assay time of 90 minutes or less, with Molecular Devices’ fluorescent CatchPoint technology to facilitate enhanced protein detection for researchers seeking a fast, reproducible, high-sensitivity solution that has been validated on the leading fluorometric instruments.

The kits will be for research use only and available via the Abcam website,
http://www.abcam.com/kits/catchpoint-simplestep-elisa-kits

References
1. Markets and Markets. 2016. Immunoassay Market - Global Forecast to 2019.

MORE ON THIS TOPIC